Bradley & Co. Private Wealth Management LLC Makes New Investment in CareDx, Inc (NASDAQ:CDNA)

Bradley & Co. Private Wealth Management LLC acquired a new stake in shares of CareDx, Inc (NASDAQ:CDNA) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm acquired 12,587 shares of the company’s stock, valued at approximately $269,000.

A number of other large investors also recently modified their holdings of CDNA. Quarry LP purchased a new stake in CareDx during the 3rd quarter valued at approximately $27,000. Harvest Fund Management Co. Ltd purchased a new position in CareDx during the third quarter valued at $52,000. KBC Group NV purchased a new position in CareDx during the third quarter valued at $99,000. Quest Partners LLC increased its holdings in CareDx by 37.8% in the 3rd quarter. Quest Partners LLC now owns 5,611 shares of the company’s stock valued at $175,000 after acquiring an additional 1,540 shares during the last quarter. Finally, Creative Planning purchased a new stake in CareDx in the 3rd quarter worth $204,000.

CareDx Stock Down 2.2 %

CDNA stock opened at $20.89 on Wednesday. CareDx, Inc has a twelve month low of $7.42 and a twelve month high of $34.84. The stock has a market capitalization of $1.12 billion, a price-to-earnings ratio of -7.74 and a beta of 1.87. The firm’s fifty day simple moving average is $22.64 and its two-hundred day simple moving average is $25.32.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on CDNA. Wells Fargo & Company raised CareDx from an “underweight” rating to an “equal weight” rating and reduced their target price for the stock from $28.00 to $24.00 in a report on Wednesday, January 15th. HC Wainwright reaffirmed a “neutral” rating and set a $26.00 price objective on shares of CareDx in a report on Tuesday, January 14th. BTIG Research reduced their price target on shares of CareDx from $40.00 to $35.00 and set a “buy” rating on the stock in a research report on Tuesday, November 5th. Finally, StockNews.com upgraded shares of CareDx from a “hold” rating to a “buy” rating in a research report on Wednesday. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, CareDx presently has an average rating of “Moderate Buy” and an average price target of $28.33.

CareDx Company Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.